Back to Search Start Over

Role of POLE and POLD1 in familial cancer

Authors :
Pau M. Munoz-Torres
Joan Brunet
Rebeca Sanz-Pamplona
August Vidal
Gemma Llort
Esther Darder
Victor Moreno
Teresa Ramón y Cajal
Laura Valle
Judith Balmaña
Marta Pineda
Tirso Pons
Xavier Matias-Guiu
Jesús del Valle
Lorena Magraner-Pardo
Rosa Aligué
Pilar Mur
Giacomo Cinnirella
Josep M. Piulats
Elia Grau
Lídia Feliubadaló
Sami Belhadj
Adriana Lopez-Doriga
Matilde Navarro
Conxi Lázaro
Sandra García-Mulero
Judit Sanz
Gabriel Capellá
Edgar Martin-Ramos
[Mur P, Del Valle J, Pineda M] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. [García-Mulero S] Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. [Magraner-Pardo L] Prostate Cancer Clinical Research Unit. Spanish National Cancer Research Center (CNIO), Madrid, Spain. [Vidal A] Department of Pathology, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. [Balmana J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
Ministerio de Economía y Competitividad (España)
Instituto de Salud Carlos III
Generalitat de Catalunya
Fundación Olga Torres
European Cooperation in Science and Technology
Source :
Scientia, Genetics in Medicine, Digital.CSIC. Repositorio Institucional del CSIC, instname, Dipòsit Digital de la UB, Universidad de Barcelona
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

[Purpose]: Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. [Methods]: POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case–control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. [Results]: Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies<br />This work was funded by the Spanish Ministry of Science and Innovation, cofunded by FEDER funds (SAF2016-80888-R, SAF2015-68016-R, Severo Ochoa SVP-2014-068895 contract [L.M.-P.]); Instituto de Salud Carlos III (PI16/00563, PI16/00588, PI14/00613, PI19/00553, CIBERONC CB16/12/00234, CIBERESP, Sara Borrell contract [P.M.]); Government of Catalonia [AGAUR 2017SGR1282, CERCA Program]; and Fundación Olga Torres. This study was facilitated by COST Action CA17118, supported by COST (European Cooperation in Science and Technology).

Details

ISSN :
10983600
Volume :
22
Database :
OpenAIRE
Journal :
Genetics in Medicine
Accession number :
edsair.doi.dedup.....359c40a1763da19d13d5833ef08af076